Clinical Trial

Short-course Radiotherapy Combined With Neoadjuvant Chemotherapy and PD-1 Inhibitor in the Treatment of Locally Advanced Gastric Adenocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 3, 2022 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Prospective, Single-center, Single-arm, phase II clinical trial to explore the efficacy and safety of sintilimab (PD1 inhibitor) combined with XELOX chemotherapy, evaluate the pathological complete response rate of short-course radiotherapy combined with sintilimab and XELOX chemotherapy in neoadjuvant therapy for locally advanced gastric adenocarcinoma.
Trial Details
NCT Number NCT05563012
Lead Sponsor Renmin Hospital of Wuhan University
Conditions Disorder in Complete Remission in Response to Treatment
Enrollment 29 participants
Start Date 2022-09-26
Primary Completion 2025-10-01 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2022-10-03